SCHEMBL4325539

SCHEMBL4325539

CC(C)CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(=O)NC(C=O)Cc1ccc(O)cc1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 1/20 0.51
REN P00797 2/20 0.49
FOLH1 Q04609 1/20 0.49
NPY4R P50391 9/20 0.48
NPY5R Q15761 7/20 0.48
NPY1R P25929 7/20 0.48
NPY2R P49146 4/20 0.48
CTSB P07858 1/20 0.47
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4325541 1.00 PSMB5 (0.51) PSMB5RENFOLH1NPY4RNPY5R
SCHEMBL29885010 0.89 GRIA1 (0.53) PSMB5
Tyropeptin A SCHEMBL29843181 0.88 CASP1 (0.50) PSMB5RENCTSB
Tyropeptin A SCHEMBL2808523 0.88 CASP1 (0.50) PSMB5RENCTSB
Tyropeptin A SCHEMBL2808528 0.88 CASP1 (0.50) PSMB5RENCTSB
SCHEMBL25627902 0.86 CTSB (0.49) PSMB5FOLH1NPY4RNPY5RNPY1R
SCHEMBL24178166 0.85 CTSB (0.56) PSMB5FOLH1CTSBOPRM1OPRD1
SCHEMBL31010534 0.84 CTSD (0.54) PSMB5RENCTSB
SCHEMBL9219464 0.84 CTSD (0.54) PSMB5RENCTSB
SCHEMBL29361872 0.84 NPY4R (0.51) FOLH1NPY4RNPY5RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023067380-A1 GENETIC SYSTEM FOR THE BIOSYNTHESIS OF LEUPEPTIN AND USE THEREOF IN HETEROLOGOUS PRODUCTION SYSTEMS CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITÉCNICO NACIONAL (MX) 2023-04-27 WO disclosed
CN-108379591-B Synthesis of immune agonist targeting compound and application thereof 深圳大学 2022-03-29 CN disclosed
EP-2061518-A2 RADIOIMAGING MOIETIES COUPLED TO PEPTIDASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES Molecular Insight Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20080213172-A1 RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-09-04 US disclosed
WO-2008028000-A2 RADIOIMAGING MOIETIES COUPLED TO PEPTIDASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213172-A1 RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES LAP3, DNPEP, ACE PSMB5 2185/4885REN 41/4885FOLH1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.